Jump to main content
Jump to site search

Issue 11, 2011
Previous Article Next Article

Natural products and Pharma 2011: Strategic changes spur new opportunities

Author affiliations

Abstract

Although natural products have been marginalized by major pharmaceutical companies over the last 20–30 years, the changing landscape of drug discovery now favors a greatly enhanced role for Nature's privileged structures. Screening for drug leads in phenotypic screens provides the best opportunity to realize the value of natural products. Advances in total synthesis, especially function-oriented syntheses and biosynthetic technologies offer new avenues for the medicinal chemical optimization of biologically active secondary metabolites. Genomic research has given new insights into biosynthetic processes as well as providing evidence that a wealth of unrealized biosynthetic potential remains to be explored. As Pharma strives to develop innovative and highly effective new drugs, natural products will be increasingly valued as sources of novel leads whose further development will be expedited by emerging technologies.

Graphical abstract: Natural products and Pharma 2011: Strategic changes spur new opportunities

Back to tab navigation

Publication details

The article was received on 14 Apr 2011 and first published on 12 Sep 2011


Article type: Highlight
DOI: 10.1039/C1NP00033K
Citation: Nat. Prod. Rep., 2011,28, 1783-1789
  •   Request permissions

    Natural products and Pharma 2011: Strategic changes spur new opportunities

    G. T. Carter, Nat. Prod. Rep., 2011, 28, 1783
    DOI: 10.1039/C1NP00033K

Search articles by author

Spotlight

Advertisements